293 related articles for article (PubMed ID: 31412875)
1. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
2. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
3. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
4. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
5. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
6. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S
Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986
[TBL] [Abstract][Full Text] [Related]
7. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
He D; Ye M; Zhang L; Jiang B
Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Kamp NJ; Chery G; Kosinski AS; Desai MY; Wazni O; Schmidler GS; Patel M; Lopes RD; Morin DP; Al-Khatib SM
Prog Cardiovasc Dis; 2021; 66():10-16. PubMed ID: 33171204
[TBL] [Abstract][Full Text] [Related]
10. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
[TBL] [Abstract][Full Text] [Related]
11. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
12. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ
JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
[TBL] [Abstract][Full Text] [Related]
14. Mortality and Sudden Cardiac Death Risk Stratification Using the Noninvasive Combination of Wide QRS Duration and Late Gadolinium Enhancement in Idiopathic Dilated Cardiomyopathy.
Marume K; Noguchi T; Tateishi E; Morita Y; Kamakura T; Ishibashi K; Noda T; Miura H; Nishimura K; Nakai M; Yamada N; Tsujita K; Anzai T; Kusano K; Ogawa H; Yasuda S
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e006233. PubMed ID: 29654132
[TBL] [Abstract][Full Text] [Related]
15. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.
Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G
Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674
[TBL] [Abstract][Full Text] [Related]
16. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
[TBL] [Abstract][Full Text] [Related]
18. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
[TBL] [Abstract][Full Text] [Related]
19. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.
Ismail TF; Jabbour A; Gulati A; Mallorie A; Raza S; Cowling TE; Das B; Khwaja J; Alpendurada FD; Wage R; Roughton M; McKenna WJ; Moon JC; Varnava A; Shakespeare C; Cowie MR; Cook SA; Elliott P; O'Hanlon R; Pennell DJ; Prasad SK
Heart; 2014 Dec; 100(23):1851-8. PubMed ID: 24966307
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
